earnings
confidence high
sentiment neutral
materiality 0.70
Tivic Health Q2 revenue down 39% to $86k; net loss widens to $1.9M; plans to exit ClearUP, focus on biopharma
Valion Bio, Inc.
2025-Q2 EPS reported
-$4.64
revenue$156,000
- Revenue $86k (-39% YoY); net loss $1.9M vs $1.3M in Q2 2024; cash $1.2M at June 30.
- Raised $0.9M post-quarter; $7M committed via preferred equity; no debt on balance sheet.
- Plans to exit ClearUP consumer healthtech by year-end; shifts resources to TLR5 agonist Entolimod.
- Extended Entolimod license to include neutropenia; completed study visits for ncVNS device.
- Named Lisa Wolf as permanent CFO; expanded biopharma team with regulatory and clinical staff.
item 2.02item 7.01item 9.01